Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | BMC Neurology

Figure 6

From: Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial

Figure 6

Clinical Global Impressions of Improvement scores. The figure shows the mean score for clinician impressions of overall improvement after 6 months of treatment. CGI-I, Clinical Global Impressions of Improvement; GA, glatiramer acetate; iDMT, injectable disease-modifying therapy; IFN, interferon; IM, intramuscular; SC, subcutaneous.

Back to article page